Vedran Pavlovic

Roche, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B.

Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B.

Journal: The New England journal of medicine

Published: January 08, 2025

Overrange dilution for improvement of hepatitis B core related antigen as a biomarker: protocol validation and examples for application.

Overrange dilution for improvement of hepatitis B core related antigen as a biomarker: protocol validation and examples for application.

Journal: Virology

Published: November 30, 2024

Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B.

Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: November 14, 2024

First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection.

First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection.

Journal: Journal of hepatology

Published: January 04, 2023

A single ascending dose study of single-stranded oligodeoxyribonucleotide RO7062931 in Chinese healthy volunteers.

A single ascending dose study of single-stranded oligodeoxyribonucleotide RO7062931 in Chinese healthy volunteers.

Journal: Clinical and translational science

Published: October 13, 2022

Reply.

Reply.

Journal: Hepatology (Baltimore, Md.)

Published: July 28, 2021

Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B.

Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B.

Journal: Hepatology (Baltimore, Md.)

Published: December 23, 2020

Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis.

Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis.

Journal: Alimentary pharmacology & therapeutics

Published: May 27, 2020

Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B.

Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B.

Journal: Journal of hepatology

Published: January 03, 2020

Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study.

Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study.

Journal: The Journal of infectious diseases

Published: October 23, 2019

Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a.

Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 05, 2019

Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.

Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.

Journal: Antiviral therapy

Published: February 24, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026